Australian Government

Australian Trade and Investment Commission

AUSTRALIAN LIFE SCIENCE MISSION TO BIOKOREA 2023

10-12 MAY 2023



AUSTRALIA

WELCOME MESSAGE

The Australia – Republic of Korea relationship in biotechnology and clinical trials is thriving.

Even while the pandemic impeded our ability to travel, the number of clinical trials of Korean therapies conducted in Australia continued to grow thanks to the high quality of our CRO sector, our fast-track clinical trials approval system and Australia's generous R&D Tax incentives.

This has led to a realisation in both countries of the opportunities for further collaboration in R&D and manufacturing that has seen new agreements signed between Australian and Korean Government agencies, research institutions and companies.

The foundations for these relationships have been built over the past 10 years, but it is perhaps the mutual recognition of the effective COVID-19 response of both countries that has focused attention of key decision makers. Australia is seen as a preferential location for productive foreign direct investment.

Backed by leading talent, an innovative ecosystem and stable political support, Australia continues to be a world leader in life sciences, clinical trials, medical devices and digital health.

The Australian Trade and Investment Commission (Austrade) continues our long-term commitment to strengthening Australia – Korea Life Science and R&D partnerships. We are pleased to welcome Australian participants to Seoul for BioKorea 2023 now fully back in-person.

The Australian mission to BioKorea 2023 (10-12 May 2023) is an important commitment by Austrade to showcase Australia's world class life science technologies in Korea and to support Australia-Korea partnerships.

The Australian delegation is the largest in its size so far and will be represented at the Australian National Pavilion at the COEX Seoul along with leading Australian presenters at the Conference sessions on vaccine and regenerative medicine as well as at Invest Fair technology streams.

The Australian National Pavilion, online partnering program, and Australia focus programs provide an exciting opportunity to meet with the Australian delegates and explore collaboration with Australian companies and research institutions.

In partnership with five state governments and supported by MTPConnect and Department of Home Affairs, the mission to BioKorea 2023 comprises 36 organisations that represent the breadth of Australian capability in the mRNA technology, regenerative medicine, clinical trials, contract manufacturing, medical research, and precision medicine.

We look forward to working with you to build closer ties between Australia and Korea in this critical sector, to generate new business opportunities, and to improve the health of our people.

Julie Quinn
Senior Trade & Investment Commissioner, Korea
Australian Trade and Investment Commission

THE AUSTRALIAN MEDICAL TECHNOLOGY AND PHARMACEUTICAL (MTP) SECTOR

1,342
MTP COMPANIES, AND
152
LISTED HEALTH COMPANIES WITH OVER
$229B
MARKET CAPITALISATION

GENEROUS R&D TAX INCENTIVE THAT OFFSETS ELIGIBLE EXPENDITURE

EFFICIENT REGULATORY PATHWAYS AND STRONG IP PROTECTION

HOME TO THE 1ST BIONIC EAR (COCHLEAR) IMPLANT, SPRAY-ON SKIN AND CERVICAL CANCER VACCINE

GOVERNMENT COMMITTED TO MEDICAL INNOVATION THROUGH THE
$20B MEDICAL RESEARCH FUTURE FUND

SET TO BE ONE OF THE LARGEST FUND OF ITS KIND IN THE WORLD

CONSISTENTLY AT THE FOREFRONT OF STEM CELL SCIENCE, DELIVERING NEW DIAGNOSTIC, THERAPEUTIC AND BIOTECH APPLICATIONS

TOP 5 IN THE WORLD FOR BIOTECH INNOVATION

A WORLD-CLASS HEALTHCARE SYSTEM WITH QUALITY MEDICAL RESEARCH INFRASTRUCTURE

IN 2021 ALONE

>1,970
NEW CLINICAL TRIALS WITH
95,000
AUSTALIANS PARTICIPATION

Source : MTPConnect Medical Technology, Biotechnology and Pharmaceutical Sector Competitiveness Plan 2022
MTPConnect Australia's Clinical Trials Sector report 2021

BioKorea 2023 Australian Participants
호주 바이오 산업 대표단

Sponsors

MTPConnect	호주 의료 기술 제약 산업 성장 센터
State Government of Victoria	빅토리아 주정부
New South Wales State Government	뉴사우스웨일즈 주정부
Trade and Investment Queensland	퀸즐랜드 주정부
Government of Western Australia	서호주 주정부
Government of South Australia	남호주 주정부
Department of Home Affairs	호주 이민성 글로벌 인재 유치 프로그램
AusBiotech	호주 바이오 산업협회

Delegates

360biolabs	임상수탁연구기관- PK/PD 시험 등 바이오 분석 및 중앙 실험실 서비스
Accelagen	호주 full-service CRO임상, RA 컨설팅 제약 생명공학 의료기기
Acclime Australia	호주 임상시험관련 정부 세제 혜택 법인 설립 컨설팅
AcuraBio	바이오의약품 개발 및 제조 CDMO
Akesa Pharma	임상시험 제품 소싱 및 유통
Amplia Therapeutics	항암제 및 섬유증 치료를 위한 FAK 저해제 연구개발
Bioforum	데이터 기반 글로벌 CRO 임상 2 3상 전문 제약 생명공학
CCRM Australia	재생 의학 기술의 상용화를 위한 전문 지식, 자금 지원 및 컨설팅 서비스 제공
Central Pharmacy Logistics	임상시험 제품 보관 및 유통
CMAX Clinical Research	초기임상 전문 사이트 (애들레이드 소재)
Crux Biolabs	R&D 및 임상 전 단계 면역학 서비스
CSIRO	호주 연방 과학 연구 기관
Epichem	의약 및 합성화학품 제조 및 분석서비스
George Clinical	아태지역 및 미국베이스의 전단계 제약 바이오 의료기기 전문 CRO
Global R&D	호주 임상시험관련 정부 세제 혜택 컨설팅
GreenLight Clinical	호주 full-service CRO전단계 임상 전문
Invion	항암제를 위한 PTD 연구개발
Linear Clinical Research	초기 및 전단계 임상 사이트 (퍼스 소재)
Microba	마이크로바이옴을 이용한 의약품 연구개발 및 분석을 통한 치료 솔루션 개발
Monash University	mRNA 백신 및 치료제, 개발 및 생산 라이프사이클 전반 지식 및 기술 개발 교육
mRNA Victoria	세계적인mRNA 연구, 개발 및 첨단 제조를 위해 설립된 빅토리아 주정부 전담 기관
NCRIS Health Group	호주의 생물학적 발견 및 중개 연구 지원 초기 전임상 개발 지원에 중점
Novotech	아태지역 및 미국·유럽 full-service CRO 전단계 임상 전문 폭넓은 제약 바이오
Nucleus Network	초기임상 전문 멀티 임상사이트 (멜버른, 브리즈번 소재)
PharmSky Research	의약품 개발 및 제조 CDMO(멸균/비멸균 액상/주사제 전문)
Recce Pharmaceutical	차세대 합성항감염제 (Synthetic Anti-Infectives) 연구개발
Sacco System Australia	마이크로바이옴 개발 및 제조 CDMO
Scientia Clinical Research	초기임상 전문 임상 사이트 (시드니 소재)
Sonic Clinical Trials	임상 전 단계 시험 분석, 환자 모니터링 및 중앙 실험실 서비스
Southern RNA	RNA 개발 및 제조 CDMO
Southern Star Research	호주 full-service CRO 초기 임상 전문 제약 바이오 의료기기
Thermo Fisher Scientific	바이오 의약품 개발 및 제조 전 과정 지원 CDMO
UNSW RNA Institute	RNA 기반 치료제 연구개발을 위한 중개서비스
Zuellig Pharma	제약 의료기기 유통 및 헬스케어 솔루션 전문 기업

Sponsors

MTP Connect

Sponsors

Stuart Dignam
Chief Executive Officer

Contact Information

Email
stuart.dignam@mtpconnect.org.au

Website
www.mtpconnect.org.au

Company Information

MTPConnect is an independent, not-for-profit organisation formed in 2015 by the Australian Government to champion the continuing growth of Australia's vibrant medical products sector.

From Nobel laureates and breakthroughs like penicillin and the cervical cancer vaccine, Australia's health and medical researchers have been responsible for some of the greatest discoveries of the modern era. With a strong ecosystem of start-ups through to manufacturing companies, Australia is uniquely positioned to foster innovative, commercial collaborations with international organisations.

MTPConnect is helping to bring life-saving medical products from bench to bedside by deploying funding to help commercialise Australian innovations and take them global. MTPConnect is also committed to engaging with international markets, leveraging networks and accessing global supply chains to make international collaborations a reality. It's all about connecting international customers with innovative Australian companies interested in expanding to international markets.

MTPConnect is headquartered in Melbourne with teams in Adelaide, Brisbane, Perth and Sydney. MTPConnect is pleased to support the Australian delegation to BioKorea and our team look forward to connecting with you.

Listen in to the MTPConnect Podcast for the latest innovation news from Australia's medtech, biotech and pharma sector (available on all podcast platforms), follow us on Twitter at @MTPConnect_AUS and LinkedIn, or join our network and subscribe to our newsletter on www.mtpconnect.org.au/network.

State Government of Victoria

Sponsors

Majella Hamilton
Trade Manager – Health and Life Sciences, Global Victoria

Contact Information

Email
majella.hamilton@global.vic.gov.au

Website
global.vic.gov.au

Minjung Kang
Trade and Investment Manager, Korea
Phone +82 2 3782 4887
Email minjung.kang@global.vic.gov.au

Biotech/Life sciences state base industry overview, capabilities

Melbourne, Victoria is one of the world's leading life science clusters. As a highly sought-after destination by global companies, the city is ranked in the top 5 of Life Science Hubs in Asia Pacific.

Melbourne is one of the few cities in the world to have two universities in the global top 40 biomedical rankings, and Monash University is ranked #2 in the world for pharmacy and pharmacology. This academic reputation produces over 24,000 graduates in health and sciences annually.

As a highly collaborative, globally connected life science ecosystem, Melbourne has 22 internationally recognised research institutes, and a network of metropolitan and regional hospitals that provide outstanding capabilities in neuroscience, oncology, genomics, cardiovascular health, regenerative medicine and infectious diseases. Centered around two co-located research precincts, Parkville and Clayton, the Victorian life science ecosystem brings together world-leading research organisations, top-tier universities and hospitals to develop revolutionary treatments and new therapies

Victoria offers a low-risk, high-quality and competitive business environment with a rich legacy of commercial success, advanced manufacturing expertise, key R&D infrastructure, attracting and maintaining a talented and skilled workforce. Industry expertise in biotechnology, medical technologies and pharmaceuticals is supported by a favourable regulatory and R&D environment and is consistently backed by strong government investment.

Victoria has over 35% of the national dedicated phase I facility beds in Australia – making it a national leader for early-stage trials. This includes specialist units focused on immunology, neuroscience, oncology, ophthalmology and pediatric diseases.

Victoria carries out about one-third of Australia's clinical trials, with over 1,924 commercial sponsored and 1,285 investigator institution sponsored trials ongoing in Victorian health services. Global companies are increasingly outsourcing early phase clinical trials, with 90% of Phase 1 clinical trials undertaken in Victoria sponsored by international firms.

New South Wales State Government

Investment NSW
Part of the New South Wales Government

Sponsors

Yoojin Kim
NSW Trade & Investment Director, Korea

Contact Information

Email
yoojin.kim@austrade.gov.au
sunah.kim@austrade.gov.au

Website
www.investment.nsw.gov.au

Biotech/Life sciences New South Wales State capabilities

NSW is innovative and entrepreneurial. The state is a world leader in medical research and is Australia's largest, globally connected state economy.

NSW's mature digital health environment is supported by 14 health precincts, two of Australia's top five highest ranked research universities and the largest number of STEM graduates in Australia.

NSW is renowned globally for its medical technology research, and the industry in NSW is Australia's largest. The state is also a global leader in biotechnology and clinical trials, with 30 per cent of all Australian trials conducted in NSW centres. It is renowned for its Statewide Biobank with over 3 million human samples and digital analysis.

A new world leading advanced viral vector manufacturing facility will be in the Westmead Health & Innovation District. A proposed new $25 million facility 'Westmead New Co' will give patients with genetic diseases, cancers and viral infections across Australia faster access to ground-breaking trial therapies.

Royal Prince Alfred Hospital is leading nationally and internationally providing FIRST clinical gene therapy trial of AAV in Australia, FIRST and ONLY site in Australia treating Thalassemia patients with gene therapy. Royal Prince Alfred Hospital officially opened the $12 million Biograph Vision Quadra PET-CT scanner in May 2021, which is the second of its kind in the world.

NSW Health's digital footprint continues to grow. 187 hospitals now use Electronic Medical Records (EMR) and 197 facilities use Electronic Medication Management (eMeds). Every Local Health District (LHD) has at least one site now live.

In partnership with industry and the community, it is also developing Tech Central which will cement Sydney as the innovation capital of Australia and as a world player in technology and incubator.

NSW is a leader in supporting international collaboration between industry, research and government. The NSW Government's Investment NSW Team, with its dedicated experts across all levels of government, provide customised support and can help business to establish, innovate and grow in Sydney and NSW. Eligible businesses can also access funding assistance through the $250million Jobs Plus Program.

Trade and Investment Queensland

Queensland Government
TRADE + INVESTMENT QUEENSLAND

Sponsors

Ryan Freer
Trade and Investment Commissioner, Korea

Contact Information

Email
ryan.freer@tiq.qld.gov.au

Website
www.tiq.qld.gov.au

Biotech/Life sciences state base industry overview, capabilities

Queensland's growing biomedical and life science sector is underpinned by internationally renowned excellence in scientific research and innovation. The state is home to more than 250 life sciences organisations, 85 core biotech companies, and 100+ biotech-related research organisations. Queensland has world-leading research institutes and science capability, with unrivalled expertise in tropical and infectious diseases and vaccine development and delivery.

Queensland is recognised around the world for its biomedical research and development. Queensland is home to world leading medical research institutes and universities leading the way in new drug discovery.

Queensland is also home to two facilities fully dedicated to the cGMP-grade contract manufacture of biopharmaceutical active ingredients. The state's streamlined clinical trial processes provide unique support to biomedical product developers, within a first-world regulatory environment that is 100% aligned with international standards.

Trade and Investment Queensland in Korea is your one-stop shop to understand and access targeted opportunities in the health, life science and biomedical industry in Queensland. Trade and Investment Queensland provides a suite of services and hands-on support for Korean organisations to enter the Australian market including partner introductions, business case studies, advice and connections on regulatory environment and information of government support and grants.

Government of Western Australia

GOVERNMENT OF WESTERN AUSTRALIA

Sponsors

Jess Ahn
WA Invest & Trade Director, Korea

Contact Information

Email
Hayley.lee@jtsi.wa.gov.au

Website
www.investandtrade.wa.gov.au

Biotech/Life sciences state base industry overview, capabilities

Western Australia (WA) has an internationally recognised medical technology and pharmaceutical (MTP) research base with significant entrepreneurial talent which achieves scientific and commercial excellence. The expertise extends to niche and specialised technologies, such as rare diseases and 'omics' technologies.

The state's capital, Perth is globally renowned as safe, clean and green, has a rapidly growing MTP sector, and is home to the WA Government funded MTPConnect WA Life Sciences Innovation Hub. The State recently launched its Health and Medical Life Sciences Industry Strategy.

Between 2017 and 2019, WA had Australia's fastest growing life sciences industry. There are multiple biotechnology and pharmaceutical companies, medtech and digital health companies, research institutions and services and support organisations.

The COVID-19 pandemic accelerated this growth by driving global interest in WA's pharmaceuticals, clinical trials, biotechnology, biological research, drug discovery and commercialisation. It enabled WA's MTP industry to draw on unique expertise from its resources and space industries to advance remote health delivery, robotics, artificial intelligence, virtual reality and wearable device technologies.

Perth has one of the largest medical precincts in the Southern Hemisphere, the Queen Elizabeth II Medical Centre. The nucleus of WA's MTP innovation ecosystem, it boasts a strong start-up ecosystem which is supported by the three hospitals, several medical research institutes and early to late stage clinical trials expertise at Linear Clinical.

WA also hosts strong data science infrastructure and high-performance computing, including the Pawsey Supercomputer, DownUnder GeoSolutions Technology's high performance computing as a service, and the Australian National Phenome Centre.

Government of South Australia

SOUTH AUSTRALIA

Sponsors

MJ (Myungjin) Kim
Senior Business Development Manager, South Australia Department for Trade and Investment –South Korea

Contact Information

Email
myungjin.kim@austrade.gov.au

Website
https://invest.sa.gov.au/sectors/health-and-medical-industries

Biotech/Life sciences state base industry overview, capabilities

The Health and Medical Industries team within the Department for Trade and Investment helps industry, business and communities identify and capitalise upon opportunities.

South Australia and its capital city Adelaide offer a world-class health and medical ecosystem.

The centrepiece of this is the Adelaide BioMed City, one of the largest health precincts in the southern hemisphere. This health research and innovation precinct features the South Australian Health and Medical Research Institute (SAHMRI), the Australian Bragg Centre which will house the only synchrotron for proton therapy in the southern hemisphere and Australia's only proton therapy centre, three universities (University of Adelaide, University of South Australia and Flinders University) and industry.

South Australia has a fantastic universal health care system and allied health network.

Adelaide features an experienced, complete ecosystem for clinical trials, including GMP manufacturing offering high quality, fast, low-cost clinical trial conduct.

We also have the world's best capabilities in artificial intelligence (AI), data analytics, machine learning and research that features across our health and medical industries, with Google Cloud, Amazon Web Services and others establishing in Adelaide targeting these capabilities.

The Department for Trade and Investment facilitate:

- companies contemplating expansion to Australia and/or the Asia Pacific region via Australia.
- companies and investors looking for investment opportunities.
- Companies who are interested in connecting with South Australian companies for services, products and/or collaboration.

Department of Home Affairs

Australian Government
Department of Home Affairs

Sponsors

Pip (Philippa) Butler
First Secretary, Global Skills Attraction

Contact Information

Email
GlobalSkillsNorthAsia@dfat.gov.au

Website
www.smartmoveaustralia.gov.au

Company Information

Australia has a blueprint for growth and prosperity powered by cutting edge technology and an unmatched lifestyle. We seek talented health professionals, innovators, entrepreneurs, multipliers, disruptors, pioneers, and outstanding leaders to support us to achieve our goals.

We are focused on attracting the best and brightest to our country, and to support you to pursue your Australian dream, we are offering a range of visa programs to support you and your family to make Australia your second home.

We have over 140,000 permanent skilled migration visa places available this year and are fast-tracking applications from people outside the country. There has never been a better time to turn your Aussie dream into reality.

If you would like to know more about what Australia has to offer you and your family, visit us at the Australia Pavilion or email us at GlobalSkillsNorthAsia@dfat.gov.au

AusBiotech

AusBiotech
AUSTRALIA'S BIOTECHNOLOGY ORGANISATION

Delegate

Lorraine Chiroiu
Chief Executive Officer

Contact Information

Email
lchiroiu@ausbiotech.org

Website
www.ausbiotech.org

Company Introduction

AusBiotech is Australia's national industry organisation, working on behalf of members for more than 35 years to provide representation and services to promote the global growth of the Australian life sciences. AusBiotech is a well-connected network of over 3,000 members in the life sciences, including therapeutics, medical technology (devices and diagnostics), and agricultural biotechnology sectors. AusBiotech is dedicated to the development, growth and prosperity of the Australian biotechnology industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world.

Areas of interest in Korean market

AusBiotech seeks to enhance connections, collaboration, and attract capital investment between Australian and Korean biotechnology companies. Connect with us if you are interested in Australia's strong companies working in regenerative medicine and cell therapies, drug discoveries, R&D, clinical trials, contract manufacturing, or medical technologies.

Delegates

360biolabs

Delegate

William Hunter
Sr. Director of Business Development APAC

Contact Information

Email
william.hunter@bioagilytix.com

Website
www.360biolabs.com

Sharon Sim
Senior Business Development Manager

Email
sharon.sim@360biolabs.com

Company Introduction

360biolabs, a BioAgilyitx company is Australia's most comprehensive specialty laboratory providing a single laboratory for all of your global clinical trial requirements. We support pharmacokinetic (PK) analysis, a diverse range of pharmacodynamic (PD) endpoints and central lab services in a quality assured environment. Our team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development.

Our global BioAgilytix team, with laboratories located in US and Germany, can support your program from discovery DMPK through to Phase 4 clinical trials. Harmonised SOPs allow for continuity post Phase 1 if you choose to conduct your early phase study in Australia followed by Phase 2 in USA or Europe.

Introduction of products and technologies

Our extensive services include LC-MS/MS, cell-based assays, immunophenotyping, cell mediated immunity, biomarkers, genomics, neutralization, virological endpoints and central lab services.

Accelagen

Delegate

Greg Plunkett
Chief Executive Officer

Contact Information

Email
Greg.plunkett@accelagen.com.au

Website
www.accelagen.com.au

Company Introduction

Accelagen is a leading and globally adept Contract Research Organisation (CRO) headquartered in Melbourne, Australia. With over a decade of delivered success, the Accelagen team's experience is widely varied across the health, wellness and disease spectrum. Accelagen offers end-to-end services across Strategic Consultation, Clinical Trials, Regulatory Affairs and Biometrics.

Accelagen works with innovative clients across the globe to make a tangible impact on the future of human health and wellness. The Accelagen team adopts a collaborative approach to partner with clients, customising solutions to meet needs while remaining cost effective through flexible and agile project delivery.

Introduction of products and technologies

Accelagen's highly skilled team delivers expertise in regulatory, clinical trial management, medical writing, biostatistics and data management. Accelagen's experience with therapeutic assets spans preclinical to Phase IV trials, and the team specialises in customising solutions for small, single-site trials for specialised therapeutics through to large multinational, always focussing on speed, quality communication and compliance. Adopting user-friendly systems and global CDISC standards, Accelagen's state-of-the-art technology delivers industry-leading insights and creates a 'shared language' for CRAs, data managers and regulators alike. Accelagen also offers authoritative guidance for strategic decision-making throughout the product lifecycle to optimise outcomes for new products.

Acclime Australia

Delegate

Blair Lucas
Group Commercial Director

Contact Information

Email
b.lucas@acclime.com

Website
https://australia.acclime.com

Company Introduction

Acclime Australia is a leading provider of professional accounting, tax, payroll, compliance, company establishment and advisory services in Australia, with a focus on providing quality outsourcing and consulting services to foreign invested clients in Australia and the region. We assist foreign invested and locally owned companies maintain the highest level of professional standards in Australia and the region through proactive compliance, reporting assistance and advice.

Acclime Australia has successfully managed the initial and ongoing Australian and US expansions for over 600 clients from a broad range of industry sectors.

Our services are delivered under a transparent, fixed-fee pricing model, so you won't pay for anything you don't need, and there are no surprises.

Introduction of products and technologies

Acclime Australia provides a comprehensive and integrated suite of incorporation, hosting and compliance solutions. When you have our expertise and knowledge on your side, you can confidently focus on building your business.

Acclime Australia specialises in supporting foreign life science companies that are entering the Australian market to conduct R&D and access the Federal government's generous R&D Tax Incentive.

Our turnkey solution provides every service you need to expand to Australia or to the USA, either as a virtual company or a fully operational physical office. From initial incorporation through to the management of your company finances and your ongoing governance and compliance needs, we'll be there with responsive and tailored support.

AcuraBio

Delegate

Carolyn Cheer
VP Business Development

Contact Information

Email
Carolyn.cheer@acurabio.com

Website
www.acurabio.com

Company Introduction

AcuraBio Pty Ltd is one of Australia's most experienced microbial fermentation CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years.

World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research.

Additional information about AcuraBio is available at www.acurabio.com

Introduction of products and technologies

Leveraging decades of expertise in microbial expression systems, AcuraBio is now adding cGMP pDNA services to its service, offering plasmid DNA for therapeutic, vaccine and diagnostic applications including mRNA and viral vector based advanced therapies.

Akesa Pharma

Delegate

George Vlascho
Director, Clinical Trial Supply

Contact Information

Email
george.v@akesapharma.com

Website
https://akesapharma.com

Company Introduction

Headquartered in Australia with global reach, Akesa specialises in supplying comparator products for clinical trials. Akesa's value to its clients is measured by our ability to fulfil product supply requests according to their exact requirements. We work collaboratively with pharmaceutical manufacturers and a network of secure and validated suppliers. We provide tailored supply chain solutions with secure and confidential supply, including large quantities, difficult-to source items and access to product documentation.

Introduction of products and technologies

Akesa has worldwide reach and specialises in supplying pharmaceutical product for clinical trial use.

We project manage your supply requirements for comparator and combination therapy medicines for use in clinical trials Phase I to IV. We also assist in supplying reference products for analytical and pre-clinical testing.

Amplia Therapeutics

Delegate

Rhiannon Jones
Chief Operating Officer

Contact Information

Email
rhiannon@ampliatx.com

Website
www.ampliatx.com

Company Introduction

Amplia Therapeutics Limited (ASX: ATX) is an Australian, clinical-stage, drug development company focused on developing orally available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases. We have two small-molecule, best-in-class FAK-inhibitors in our pipeline, AMP945 and AMP886.

In cancer, FAK inhibitors are known to enhance the activity of chemotherapies, immunotherapies and radiotherapy through modulation of the tumour microenvironment, and we are looking for partners who are interested in exploring the clinical potential of our drugs in various solid cancers, in combination with their own drugs.

Introduction of products and technologies

Amplia is developing FAK inhibitors for use in oncology and fibrotic diseases.

AMP945 is the best-in-class FAK inhibitor and shows the highest selectivity amongst those in active clinical development. Higher selectivity is underlined by a favourable safety and tolerability profile in its recently completed phase 1 program.

AMP945 will shortly be entering a Phase 2 trial in Pancreatic Cancer (in combination with standard of care) with sites in Australia and Korea. We are currently in the dose-finding phase of this trial.

AMP945 has been awarded Orphan Drug Designation by the US FDA for use in treating pancreatic cancer and IPF.

Bioforum

Delegate

Otto Damsma
Vice President APAC Operations

Contact Information

Email
otto.damsma@bioforumgroup.com

Website
https://bioforumgroup.com

Company Introduction

Bioforum – The Data Masters, is an international data focused CRO. We have highly experienced teams in Clinical Data Management, Biostatistics & Statistical Programming, and Medical Writing.

Bioforum supports pivotal phase 2-3 studies for registration as a central data centre ensuring data consistency and cost efficiencies across studies in your (global) clinical development program.

Our approach enables efficient creation of Clinical Study Reports and eCTD documents, and swift creation of SDTM/ADaM Data Submission packages that are part of registration dossiers (NDA, MAA, BLA, PMA), for submission to the Regulatory Authorities in different countries across the globe.

Introduction of products and technologies

In Clinical Data Management supports the following EDC systems: Medidata Rave EDC, Viedoc, Veeva CDMS, Medrio, and MedNet.

A unique capability is Bioforum's own validated software (Jet-Convert) for automated conversion of raw clinical study data to validated SDTM datasets + automated creation of the fully compliant SDTM Submission Packages (for FDA, PMDA, etc.).

Business benefits: deliver twice as fast as other service providers and at lower cost, and superior quality, especially since there are no SAS Programmers involved.

CCRM Australia

Delegate

Dr Chih Wei Teng
Chief Operating Officer

Contact Information

Email
chihwei.teng@ccrmaustralia.com.au

Website
www.ccrmaustralia.com.au

Company Introduction

CCRM Australia accelerates the commercialisation of regenerative medicine therapies and related technologies. We provide specialist expertise, funding opportunities and connections between industry, clinicians, researchers, and other key stakeholders.

Introduction of products and technologies

CCRM Australia offers market consulting services to understand/validate the potential of their technology, such as identifying problems and unmet needs, determining ideal customer profile and market size, understanding the competitive landscape and creating a Target Product Profile. Other services include providing connections to industry, venture capital, and academic collaborators.

CCRM Australia will be establishing a Translation and Commercialisation Facility that will offer fee for service preclinical activities that will include process development, scalability and automation, determination of good laboratory practices for a given protocol, assay development, clinical study design, scale-up for Phase I, process transfer to cGMP facility.

Central Pharmacy Logistics

Delegate

Rima Darwiche
Chief Executive Officer

Contact Information

Email
rima@cplaustralia.com

Website
https://cplaustralia.com

Company Introduction

CPL offers the full end to end supply chain solution for conducting a clinical trial in Australia. CPL's facilities are licenced by the Therapeutic Goods Administration (TGA) for manufacture, warehousing and distribution of investigational products and ancillary supplies for clinical trials both locally and globally. CPL are also licenced by the Victorian Pharmacy Authority to dispense investigational product directly to a patient's or participant's home safely, privately, and securely, this is also known as Direct to Patient (DTP).

Introduction of products and technologies

With our GMP facility close to Melbourne Airport, we can assist you with early phase I to commercial stage clinical trial support in Australia and New Zealand:

- Clinical Supply Importation
- Comparator Sourcing & Blinding
- Release for supply
- Packaging & Labeling
- Licenced Direct-to-Patient Shipments and Decentralized Trials support
- Ancillary Supplies
- Environmentally Controlled Worldwide Storage & Distribution Network

CMAX Clinical Research

Delegate

Zoe Harrison
Chief Business Development Officer

Contact Information

Email
Zoe.harrison@cmax.com.au

Website
www.cmax.com.au

Company Introduction

CMAX Clinical Research has been a leader in delivering early phase clinical trials for 30 years, making it one of the most respected clinical trial businesses in Australia.

Our modern custom-built facility is equipped with 78 inpatient beds and located opposite Adelaide's Bio-Med City, providing ready access to state-of-the-art facilities, equipment and world-class medical specialists.

Australian clinical trials are known for their quick start-up timelines, cost competitiveness and for their quality. CMAX's services are eligible for the generous Australian R&D Tax Incentive scheme. Australian data is internationally recognised by the FDA and other regulatory agencies.

Introduction of products and technologies

- Complex adaptive FTIH protocols, including single ascending dose, multiple ascending doses (SAD/MAD)
- Food-effect studies, Drug-drug interaction (DDI) studies
- Bioequivalence/bioavailability/PK studies (505b2 programs)
- Vaccine studies at all phases
- Biosimilar protocols
- Early phase patient studies (currently no oncology), including proof-of-concept studies
- Experienced in most drug types; small and large molecule, GMO and gene therapies and most routes of administration;
- Work in most therapeutic areas, able to support EEG monitoring, CSF sampling and 12-lead holter monitoring

Crux Biolabs

Delegate

Paul Della Gatta
Business Development manager

Contact Information

Email
paul.dellagatta@cruxbiolabs.com

Website
www.cruxbiolabs.com.au

Company Introduction

Crux Biolabs is an immunology service lab, with expertise customizing and running biomarker and cell-based tests for clinical trials and pre-clinical R&D.

Introduction of products and technologies

We offer a full suite of immunology services, we have expertise in bespoke test development and experience across a broad of therapeutic areas. Our services include:

- **Large molecule PK** (absorbance/MSD based)
- **PD biomarkers**
- **Multiplex array** (Luminex/MSD) (Cytokine/inflammation panels, cancer biomarkers, growth factors, metabolic biomarkers)
- **ELISA** (absorbance/MSD based)
- **EliSpot/Flurospot**
- **Anti-drug Antibodies** (ADA)
- **Nucleic acid extraction** (RNA, DNA, ctDNA)
- **PBMC processing** (SepMate, CPT, traditional)
- **Cell culture and functional assays** (PBMCs, Primary Cells, CAR-T)
- **Flow cytometry** (21-colour, intracellular cytokine staining, immunophenotyping, receptor occupancy, functional assays)

CSIRO

Delegate

Bevan Morton
Business Development Manager, Health and Biosecurity

Contact Information

Email
bevan.morton@csiro.au

Website
www.csiro.au

Company Introduction

CSIRO is Australia's National Science Agency, and for over a century have used science to improve lives and solve the greatest challenges through innovation and technology.

CSIRO's deep and broad relationships have brought together the best minds to work across industry, government, and research to deliver innovative solutions and improvements in areas such as energy and biosecurity, manufacturing and healthcare.

Mixing science with world-class national facilities and collections, CSIRO uses strong and collaborative commercial partnerships and engagement, both nationally and internationally, to perform brilliant science and deliver impactful, innovative and accessible outcomes for communities across the globe.

Epichem

Delegate

Anusha Aubert
Business Development Manager

Contact Information

Email
Anusha.aubert@epichem.com.au

Website
www.epichem.com.au

Company Introduction

Epichem is a Perth based contract research organisation (CRO) that specialises in medicinal, synthetic, and analytical chemistry. With over 20 years of experience in the industry, Epichem has been a key contributor to developing novel compounds that have the potential to positively impact diseases such as oncology, HIV, Hepatitis C, rare and infectious diseases.

Introduction of products and technologies

Drug discovery, tailored hit to lead optimization project research service

Pharmaceutical Reference Materials

Custom synthesis of small molecules

Analytical chemistry testing services

George Clinical

Delegate

Elisabeth Yunarko
Business Development Director

Contact Information

Email
eyunarko@georgeclinical.com

Website
www.georgeclinical.com

MiSoon Seo
Country Manager

Email
mseo@georgeclinical.com

Company Introduction

Founded in Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical is a leading, global clinical research organization with more than 450 people in 19 locations able to manage clinical trials in 70 geographies throughout the Asia-Pacific region, USA and Europe.

Introduction of products and technologies

As therapeutic specialists in kidney and metabolic, endocrinology, oncology, vascular and respiratory, our unmatched scientific leadership provides the full range of clinical trials services to pharmaceutical, medical device and diagnostic customers for all trial phases, registration and post-marketing trials.

Global R&D

Delegate

Dr Pavel Reddy
Founder / R&D Tax Advisor

Contact Information

Email
pavel@globalrnd.com.au

Website
https://globalrnd.com.au

Company Introduction

Global R&D is a dedicated R&D Tax Incentive consultancy with a truly global reach. We provide valuable, expert guidance on all aspects of R&D Tax matters to companies across Australia, China, and the USA.

Founder and Director, Dr Pavel Reddy comes with 15+ years of R&D Tax expertise, having worked for a Big Four firm, as well as another local respected R&D Tax advisory firm. With a Doctorate in Biology and a two-decade academic career in the Sciences, Pavel is well-placed to identify and understand the technology that underpins R&D Tax Incentive claims across several sectors.

Pavel has also met the requirements for R&D Tax Agent registration and is currently registered with the Australian Government's Tax Practitioners Board.

Introduction of products and technologies

Working actively across the start-up and SME community, Global R&D provides R&D Tax Advisory services across the various Tech sectors, including but not limited to AgriTech, BioTech, FinTech, Life Sciences, MedTech, Manufacturing, Mining and Pharma.

In addition to providing insightful and expert advice, trusted guidance, and focused resources to ensure compliant R&D Tax Incentive claims, Global R&D has already enabled clients to receive cash refunds that exceed client expectations.

GreenLight Clinical

Delegate

Grace Pei
Chief Executive Officer

Contact Information

Email
Grace.pei@greenlightclinical.com

Website
www.greenlightclinical.com

Company Introduction

GreenLight Clinical is a physician-led, boutique full-service clinical CRO with its own central clinical, bioanalytical, histopathology laboratories in Sydney, Australia. We have offices in Australia and USA, with presence in the APAC region. Our niche is to support clinical trials for biotech and MedTech companies. We help you take advantage of the speed of study start-up and R&D tax incentives in Australia and allow for a smooth trial transition to the US. Combining medical expertise and deep industry knowledge, we develop bespoke solutions to accelerate your innovative treatment development for patients with unmet needs.

Introduction of products and technologies

We are the only Australian full-service CRO with an in-house NATA accredited central clinical laboratory, offering safety testing (biochemistry and hematology), a bioanalytical laboratory offering biomarker and pharmacokinetic/pharmacodynamic (PK/PD) testing, and a histopathology laboratory for cell/tissue based market evaluation. Our CRO services are full service including project management, study feasibility and startup, clinical operations, data management and biostatistics analysis, safety reporting and medical monitoring, regulatory affairs, and medical writing. Our tailored solutions help to accelerate your innovative treatments can be accessed quicker by patients with unmet medical needs.

Invion

Delegate

Scott Carpenter
Program Director

Contact Information

Email
Scott.carpenter@inviongroup.com

Website
www.inviongroup.com

Company Introduction

Australian life-sciences firm Invion is leading the global clinical development of a novel PhotoDynamic Therapy (PDT) for cancer. Invion's novel photosensitiser (the agent used in PDT) is called IVX-PDT and is based on the PhotosoftTM Technology.

Introduction of products and technologies

Photo Dynamic Therapy (PDT) is a proven treatment that optimises the use of non-toxic photosensitisers and visible light to kill cancer and stimulate the immune system. Invion is developing the next-generation PDT that is more effective and overcomes the many shortcomings of current PDT treatments.

Linear Clinical Research

Delegate



Shu Lam
Head of Business Development

Contact Information

Email
slam@linear.org.au

Website
www.linear.org.au

Company Introduction

Linear Clinical Research is an innovative, 48-bed, not-for-profit clinical trial facility based in Perth, Western Australia. Linear has worked on over 430 studies since its formation in 2010 across a wide range of therapeutic areas. With two state-of-the-art clinical facilities, Linear can support the execution of all trial phases with a key focus on delivering your study as fast as possible (e.g. approx, 40 days to ethics approval) without compromising on quality and data integrity.

Introduction of products and technologies

At Linear, the focus is on its facilities to support first in human through to Phase II proof of concept clinical trials and we support studies in most therapeutic areas spanning oncology and non-oncology. Linear has extensive experience in both healthy volunteers and patients studies.

Linear has a variety of departments from clinical strategy development, project management, medical, start-up, recruitment, clinical, data management, quality assurance and laboratory. They work together to ensure high-touch customer service and accelerated clinical delivery to the highest safety and quality standards.

Linear is the Asia Pacific site leader in electronic source data platform, which allows quality assurance, real time access to data for efficient decision making, streamlined monitoring, resulting in trials being completed and locked faster.

Microba

Delegate

Seong Min, Baek
Partnership Manager

Contact Information

Email
Seongmin.baek@microba.com

Website
https://microba.com

Company Introduction

Microba Life Sciences is a precision microbiome company driven to advance health.

With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases, cancers and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.

Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new healthcare solutions.

Introduction of products and technologies

Using advanced metagenomic sequencing technology and proprietary bioinformatic tools, Microba provides precise and comprehensive measurement of the human gut microbiome.

Also through its world-leading technology, Microba has generated a large databank of metagenomic gut microbiome samples and associated health and diet data to realise these opportunities.

Microba's Discovery Platform enables partners to access this databank for data-driven discovery of product opportunities.

Monash University

The Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training

Delegate

Prof. Jennifer Short
Director

Contact Information

Email
mRNAMedicines.
WorkforceTraining@monash.edu

Website
www.monash.edu/mrna-workforce-training-centre

Company Introduction

The Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training is a newly established educational centre, with a clear remit to establish knowledge and skill development across the mRNA vaccine and therapeutic discovery, development and production life cycle, and to support growth of the mRNA manufacturing sector through delivery of technical competencies and practical, hands-on training.

Introduction of products and technologies

We deliver best-practice education and training programs across the mRNA vaccines and therapeutics pipeline – from research and development, through clinical trials and approval, to production scale-up and manufacture, and beyond. The Centre is collaborative and consultative in its approach to designing, developing and delivering workforce training programs and welcomes participants from a range of disciplines and/or backgrounds from around the world. Our target audience includes potential students, participants and collaborators from academia and industry.

mRNA Victoria

Delegate

Rebecca Skinner
Director, Research and Industry Development

Contact Information

Email
rebecca.skinner@ecodev.vic.gov.au

Website
https://djsir.vic.gov.au/medical-research/initiatives/mrna-victoria

Company Introduction

mRNA Victoria is a dedicated government agency established to lead mRNA research, development, and advanced manufacturing to establish a world-class Australian mRNA industry, based in Melbourne, Victoria, Australia.

mRNA Victoria is building an end-to-end ecosystem through industry partnerships, supporting supply chain development, pre and clinical research, commercialisation, international investment and manufacturing.

In 2022, mRNA Victoria signed a Memorandum of Understanding with the Korean Health, Industry Development Institute (KHIDI) to collaborate on mRNA research and manufacturing to boost the development of RNA ecosystems in both jurisdictions.

Introduction of products and technologies

mRNA Victoria is overseeing delivery of:

- Moderna's new Australian population-scale commercial mRNA vaccine manufacturing facility currently under construction.
- BioNTech's clinical-scale manufacturing and research translation facility in Melbourne, Australia
- Research grant programs to research institutions for breakthrough and discovery research for new mRNA-based vaccines and therapies
- The Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training, a dedicated centre at Monash University training the future mRNA workforce from Australia and the Asia-Pacific
- Global partnerships with international jurisdictions and RNA companies

NCRIS Health Group

Delegate

Dr John Parisot
Business Development Manager/ Strategic Partnerships Advisor

Contact Information

Email
j.parisot@therapeuticinnovation.com.au

Website
www.therapeuticinnovation.com.au
https://phenomicsaustralia.org.au
www.bioplatforms.com

Company Introduction

The NCRIS Health Group invests in nationally significant medical research infrastructure. It focusses investment in people, projects (via access vouchers), equipment and partnerships to support researchers working on product types accounting for the majority of therapeutics currently in development. This includes small molecules, proteins, antibodies, vaccines, RNA, and cell/gene therapy medicinal products. The NCRIS Health Group strategy focusses on early preclinical development where there is a dearth of support that researchers must navigate to translate a discovery from a lab setting into a medical/health impact. It helps product development projects cross this boundary by addressing identified capacity and capability gaps.

Introduction of products and technologies

The NCRIS Health Group has been established to enable the translation of biological discoveries in Australia within the following core areas of health research:

(1) Disease modelling
(2) Target discovery and validation
(3) Therapeutic and diagnostic development
(4) Scale-up and manufacturing
(5) Clinical trials
(6) Patient outcomes
(7) Population Health

Specifically, it provides services to Australian researchers and industry requiring access to the latest innovations in genomics, proteomics, metabolomics, bioinformatics, in vivo and in vitro disease phenotypic modelling, genome engineering, functional genomics, biobanking and pathology. Further down the pipeline, it provides services for development of Biologics; Pharmaceutical Drug Development, Cell and Gene Therapies and RNA Therapeutics.

Novotech

Delegate

Lilian Kim
Senior Director Business Development

Contact Information

Email
Lilian.Kim@novotech-cro.com

Website
https://novotech-cro.com

Company Introduction

Novotech is internationally recognized as the leading Asia Pacific centred Biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 3000 staff globally and 34 office locations.

Introduction of products and technologies

Expertise & Solutions

- **Full clinical services** from first-in-human (FIH) to phase IV clinical studies.
- **Expert Consulting Services:** Clinical and Regulatory Strategy, Drug Development Consulting (DDC), CMC, Toxicology & other nonclinical consulting, GMP Consulting, etc.
- **Medical and Regulatory Consulting:** Offering full range of pre-clinical, regulatory affairs support, medical and pharmacovigilance consulting services.
- **Biometrics and Data Management:** Delivering biostatistics in clinical trials services including statistical planning, analysis, and reporting.
- **Clinical Operations and Project management:** Clinical trial monitoring, management, Patient recruitment, Feasibility assessment and Site Management (SMO), etc.
- **Real World Data (RWD):** Accelerating patient recruitment and Drug Development with RWD
- **Independent QA services:** Accredited to ISO (International Standards Organization) 9001
- **Robust IT systems:** Accredited to ISO 27001 (Information Security Management System)

Related Trial Services

- 1 Central Lab and 2 Dedicated Phase I Units
- SMO capability across South Korea and China
- Lab service in South Korea

Nucleus Network

Delegate

Jeffery Wong
Director of Business Development

Contact Information

Email
j.wong@nucleusnetwork.com.au

Website
www.nucleusnetwork.com

Company Introduction

Nucleus Network is the only Phase I clinical trial specialist with operations in both Australia and the USA. We have three units with 220+ beds and conduct a broad range of early phase clinical trials including FIH, DDI, TQT, Vaccine, Renal/Hepatic Impairment and Biosimilars.

We are Australia's largest Phase I clinical trial provider with two clinics located in the major cities of Melbourne and Brisbane enabling access to >50% of the country's population. Our large molecule Center of Excellence in Brisbane has been dedicated to development of New Biological Entities, Biosimilars and Vaccines for more than 20 years. This specialization leads to better recruitment outcomes for our sponsors and their programs. Our US clinic resides in the biotech hub of Minneapolis, Minnesota enabling us access to a total of more than 18 million people across all three sites.

Introduction of products and technologies

As a dedicated clinical trial operator, Nucleus Network provides premium services in the conduct of early phase clinical trials which include protocol and Investigator's Brochure review, volunteer recruitment, regulatory submission, trial conduct, collection and management of biological samples, investigational product management, data entry and data archival. Nucleus Network specialises in healthy volunteer clinical trials and has experience across a broad range of therapeutic areas which include (but not limited to) respiratory, neurology, immunology, infectious diseases, gastroenterology, dermatology, cardiaology, ophthalmology, nephrology and women's health.

PharmSky Research

Delegate

Marlen Yanni
Quality and Business Development Manager

Contact Information

Email
marlen.yanni@pharmsky.com.au

Website
http://pharmsky.com.au

Company Introduction

PharmSky Research provides premium contract research, drug development services for domestic and international clients. Our team is made up of a diverse group of scientists with decades of big pharma experience, providing you with expert services in development and registration support for complex generic drug products. Highly skilled in formulation and analytical development, we specialize in pharmaceutical development across a wide range of complex dosage forms to support early stage and clinical studies. Equipped with modern and specialized equipment, we have extensive analytical capabilities to provide assurance of the quality, safety and efficacy of products.

Introduction of products and technologies

PharmSky Research tailors' solutions to our clients unmet needs. Services include New product design, complex formulation development, Manufacture process development and scaling up support, analytical method development and validation, ICH/GMP analytical testing, Preclinical study material production and product development for clinical trial (Phase 1) studies.

Recce Pharmaceutical

Delegate

James Graham
Chief Executive Officer

Contact Information

Email
marketing@recce.com.au

Website
www.recce.com.au

Company Introduction

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development.

Introduction of products and technologies

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

Sacco System Australia

Delegate

Howard Kim
Business Development Korea

Contact Information

Email
howard.kim@saccosystem.com

Website
www.saccosystem.com

Company Introduction

Sacco System has been producing highest quality dairy enzymes, food cultures & probiotics for food and pharma since 1872.

Sacco System is the international biotech hub for food, nutraceutical, and pharmaceutical innovation.

Innovative and customized solutions capable of responding to modern challenges of the Food & Health sector worldwide.

We develop and produce probiotics, postbiotics (including EV's), next-generation bacteria and live biotherapeutics (LBPs)

Introduction of products and technologies

Sacco System offers a complete suite of services to develop and scale up Probiotics, Postbiotics and Microbial Therapeutics for supplement, biotech and pharma companies.

This expertise includes the development of processes and dossiers for aerobic and anaerobic strains including:

- Media screening and optimization
- Analytical method development and validation
- Cell bank preparation and validation (RCB, MCB and WCB)
- Process development and scale up
- Lyophilization
- Production in GMP from clinical to industrial scale (20,000L)
- Stability studies

Sacco system also has many own strains that are clinically proven (Culture Science) or well characterized (Culture Select). These are produced to the highest quality standards to support your needs.

Scientia Clinical Research

Delegate

Lisa Nelson
Chief Executive Officer

Contact Information

Email
Lisa.nelson@scientiaclinicalresearch.com.au

Website
www.scientiaclinicalresearch.com.au

Company Introduction

Scientia Clinical Research (SCR) is a not-for-profit early phase clinical trial company. SCR operates a 30-bed phase I unit co-located within the Prince of Wales Hospital a tertiary teaching hospital offering a full range of clinical specialties.

SCR conducts approximately 30-35 clinical trials per year, including 20-25 First Time In Human (FTIH) single and multiple dose studies, food effect studies, drug interaction studies, ethnopharmacology studies (Korean, Japanese, Chinese), biosimilar studies, formulation studies and specialty studies incorporating a range of pharmacodynamic markers such as Flow Cytometry and Cytokine analysis.

These studies are being performed in healthy volunteers as well as patient populations such as oncology, haematology, parkinson's disease, diabetes, fibrosis and NASH. The majority of our sponsors are multinational pharmaceutical and biotechnology companies.

Australia has a fast & pragmatic clinical trial approval scheme. All clinical trials are submitted to the local Ethics Committee for review. SCR ethics review cycle is approximately 4-6 from submission to approval. This allows first dosing to occur 6-8 weeks from submission to Ethics.

SCR can manufacture finished product (investigational product) from active pharmaceutical ingredients and manage investigational product importation, receipt and labelling. These services have provided significant time and cost savings to our Sponsors.

Company product and/or service introduction

Perform early phase clinical trials for multinational pharmaceutical and biotechnology companies

Sonic Clinical Trials

Delegate

Simon Dixon
Director, Commercial Services

Contact Information

Email
sdixon@sonicclinicaltrials.com

Website
www.sonicclinicaltrials.com

Company Introduction

Sonic Clinical Trials is Australia's leading dedicated central laboratory service provider. Sonic has managed more than 2,500 trials, servicing over 5,000 clinical sites globally. Our dedicated, state-of-the art central laboratory supports all phases of clinical trials throughout the biotech, pharmaceutical and research sectors.

Collaborating with our global laboratory partners and supported by Sonic Healthcare affiliate laboratories in the UK and USA, Sonic Clinical Trials provides regional and global laboratory processing, analysis, sample management and project management.

Sonic also leverages Australia's largest diagnostic laboratory network, offering the dual advantage of central or local laboratory analysis, depending on the study requirements.

Introduction of products and technologies

Sonic Clinical Trials can directly access the vast infrastructure and resources of Sonic Healthcare's extended group of specialist diagnostic practices, throughout the UK, Europe and the USA to provide an even broader range of services and medical expertise.

Sonic is also one of the largest radiology and primary healthcare providers in Australia, and is supported by a network of more than 1,000 specialist pathologists across all therapeutic indications, as well as expert radiologists and GPs.

Southern RNA

Delegate

Garry Heaney
Head of Operations

Contact Information

Email
Garry.heaney@southernrna.com.au

Website
https://southernrna.com.au

Romain Tropée
Production Lead

Email
romain.tropee@
southernRNA.com.au

Company Introduction

Southern RNA is a leading Contract Development and Manufacturing Organization (CDMO) specializing in high-quality nucleic acid production and manufacturing services. We provide custom solutions for plasmid DNA (pDNA) and messenger RNA (mRNA) synthesis, purification, and QC. Our team of experienced scientists is dedicated to delivering excellence in operation, customer service and technical support. We work closely with our clients to understand their specific needs and provide tailored solutions to meet their requirements. At Southern RNA, we are committed to producing high-quality products, ensuring timely delivery and within budget to support our clients' research and development efforts.

Introduction of products and technologies

Southern RNA is leading the provision of raw materials for the mRNA vaccine industry in Australia. Our expertise in nucleic acid production and manufacturing allows us to offer high-quality plasmid DNA production with low endotoxin and mRNA Drug substance production services for the development of mRNA-based vaccines and therapeutics. Our Co Cap™ A reagent, a co-transcriptional capping reagent, is a key component in the production of mRNA molecules and ensures optimal activity and quality of the final product. Our commitment to quality and technical expertise ensures that our clients receive the highest quality raw materials for their mRNA vaccine and therapeutic development needs. Contact us today to learn more about our products and services.

Southern Star Research

Delegate

Dr David Lloyd
Managing Director

Contact Information

Email
david@southernstarresearch.com

Website
www.southernstarresearch.com

Company Introduction

Southern Star Research is a leading Australian, full-service Contract Research Organization. We specialize in providing early phase clinical research support to biotech, device and pharmaceutical sponsors looking to accelerate their clinical program in Australia and springboard their clinical program into the US, Europe and South-East Asia. Headquartered in Sydney, we actively support studies in Australia, New Zealand, US, Europe and South-East Asia across a range of different therapeutic areas including Oncology, Neurology, Endocrinology, Infectious Disease, Pediatric as well as emerging Cell & Gene Therapies.

Introduction of products and technologies

Project Management

Clinical Monitoring & Operations

Biostatistics & Data Management

Medical Monitoring & Safety

Study Feasibility

Quality Assurance

Medical Writing

Regulatory Affairs

Local Sponsorship

Thermo Fisher Scientific

Delegate

Hyeeun Choi
Senior Marketing Specialist

Contact Information

Email
hyeeun.choi@thermofisher.com

Website
www.thermofisher.com/patheon

Company Introduction

Thermo Fisher Scientific provides industry-leading pharma services solution s including end-to-end drug development, clinical trial services and commercial manufacturing solutions to customers of all sizes through our Patheon brand. With more than 60 locations around the world, the company has extensive capabilities including small and large molecule drug substance and drug product development, viral vector and cGMP plasmid development and manufacturing to support cell and gene therapy and vaccines, clinical trial services and commercial-scale manufacturing and packaging.

Introduction of products and technologies

Patheon pharma services, Thermo Fisher Scientific's CDMO business, provide industry-leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers. With more than 60 locations around the world, we provide integrated, end-to-end capabilities across all phases of development, including API, biologics, viral vectors, mRNA, cGMP plasmids, formulation, clinical trials solutions, logistics services and commercial manufacturing and packaging. We give pharma and biotech companies of all sizes instant access to a global network of facilities and technical experts across the Americas, Europe, Asia and Australia. Our global leadership is built on a reputation for scientific and technical excellence. We offer integrated drug development and clinical services tailored to fit your drug development journey through our Quick to Care program. As a leading pharma services provider, we deliver unrivaled quality, reliability and compliance. Together with our customers, we're rapidly turning pharmaceutical possibilities into realities.

UNSW RNA Institute

Delegate

Andre Serobian
Chief Innovation and Commercialisation Officer

Contact Information

Email
a.serobian@unsw.edu.au

Website
www.unsw.edu.au/research/rna-institute

Company Introduction

The UNSW RNA Institute links and expands multidisciplinary teams in RNA biology, RNA chemistry and RNA medicine, with clinical experts and services, underpinned by a pilot-scale ISO 9001 Certified RNA accelerator facility.

The UNSW RNA Institute was established to translate the potential of bioscience into the products that will improve our health and the quality of our lives. These products are the vaccines and treatments for emerging diseases such as COVID-19, but also therapeutics for the yet more complex challenges of cancers, infectious, rare genetic and neurodegenerative diseases – all areas to be pioneered by the UNSW RNA Institute.

Introduction of products and technologies

The RNA Accelerator, gives clients access to RNA-based therapeutics and key intermediates at a quality and scale suitable for pre-clinical studies. The RNA Accelerator is supported by the NSW RNA Production and Research Network, which aims to make capabilities available state-wide to academic partners as well as industry.

The RNA Accelerator offers capabilities across the development and production pipeline for RNA-based therapeutics including:

- Plasmid DNA production, purification and characterisation
- mRNA production, purification and characterisation
- Synthetic RNA and DNA production, purification and characterisation (including siRNA, gRNA and oligoDNA)
- Lipid NP formulations, purification and analysis

Zuellig Pharma

Delegate



Lynn Mills
Clinical Reach, Business Development Manager

Contact Information

Email
Lynn.mills@zuelligpharma.com

Website
www.zuelligpharma.com

Company Introduction

Zuellig Pharma Clinical Reach provides the best solution for clinical trial Investigational Product management throughout the APAC region and has a global reach.

Zuellig Pharma Group work with global, region and local clients, providing sustainable one-stop clinical logistics supply chain solutions and clinical sourcing for Multi-Regional Clinical Trial through ZP global network to ensure your clinical trials.

Introduction of products and technologies

Zuellig Pharma Clinical Reach provide professional clinical trial logistics experience, expertise, and commitment to Zuellig Pharma's code of conduct and quality guidelines, in compliance with GCP/GMP.

Zuellig Pharma also provides Repacking services and sustainable IP supply chain management for your clinical trial.

IN PARTNERSHIP WITH

MTPConnect
MedTech and Pharma Growth Centre

GLOBAL VICTORIA
Australia

Investment NSW
Part of the New South Wales Government

Queensland Government
TRADE + INVESTMENT QUEENSLAND

GOVERNMENT OF WESTERN AUSTRALIA

SOUTH AUSTRALIA

Australian Government
Department of Home Affairs

AusBiotech
AUSTRALIA'S BIOTECHNOLOGY ORGANISATION

ABOUT AUSTRADE

The Australian Trade and Investment Commission (Austrade) is Australia's leading trade and investment agency.

We are experts in connecting Australian businesses to the world and the world to Australian businesses.

Austrade is the national point-of-contact for investors. We partner with state and territory governments to provide the information and contacts you need to establish or expand a business in Australia.

We help companies around the world to identify and take up investment opportunities in Australia as well as to source Australian goods and services for their global supply chains.

Contact us to discover how we can help you and your business.

Austrade Key Contacts

Seoul

Julie Quinn
Senior Trade & Investment Commissioner, Korea
Direct Phone: +82 2 398 2801
E: Julie.quinn@austrade.gov.au

Juliet Woo
Director, Trade and Investment
Direct Phone: +82 2 398 2809
E: Juliet.woo@austrade.gov.au

www.austrade.gov.au/korea

Australian Government
Australian Trade and Investment Commission

Australian Government

Australian Trade and Investment Commission



AUSTRALIA